Navigation Links
CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
Date:1/29/2009

on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CRGN-F

- FINANCIAL TABLES ATTACHED -

                       CURAGEN CORPORATION AND SUBSIDIARY
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                      (in thousands, except per share data)


                                   Three Months
                                      Ended                Y
'/>"/>
SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Reports Third Quarter 2008 Financial Results
2. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
3. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
4. CuraGen to Present at the BIO CEO & Investor Conference
5. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
9. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
10. CuraGen Appoints Clinical Oncologist as VP of Medical Development
11. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... BETHESDA, Md., Sept. 16 Micromet, Inc. (Nasdaq: MITI ), ... inflammation and autoimmune diseases, today announced that its President and CEO, Dr. ... September 22, 2009 in New York City. A simultaneous webcast of ... , , ...
... ... RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential ... ... research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic ...
... , , CINCINNATI, Sept. 16 ... research organization, today announced the Company will participate in the upcoming ... Grand Hyatt New York Hotel in New York City. , ... , , Kendle,s formal presentation will be given ...
Cached Biology Technology:Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 2Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 3CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 2CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 3Kendle to Present at UBS Global Life Sciences Conference 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A new study that provides a snapshot of a ... of physical activity are strongly associated with being overweight or ... in fruits and vegetables did little to offset the effect ... who were mostly sedentary. Instead, exercise seemed to be the ...
... March 24 An experimental vaccine against an abnormal protein ... onset of inflammatory bowel disease (IBD) and in turn prevent ... of Pittsburgh School of Medicine. Their findings are reported this ... the American Association for Cancer Research. People with chronic ...
... A Worcester Polytechnic Institute (WPI) research team has ... Institutes of Health (NIH) to continue a groundbreaking study ... that will enable physicians to predict the likelihood of ... and strokes. Led by Dalin Tang, PhD, professor of ...
Cached Biology News:Rochester study connects workplace turmoil, stress and obesity 2Rochester study connects workplace turmoil, stress and obesity 3Rochester study connects workplace turmoil, stress and obesity 4Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 3
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... Sytem is a highly advanced digital ... digital imaging and automation technology that ... analysis, archving/retrieval and colored professional reporting. ... imaging system that aids in performing ...
... APO-DIRECT is a single-step staining method ... cells by flow cytometry. The kit contains ... apoptosis in cells including: positive and negative ... reaction and rinsing buffers for processing individual ...
Biology Products: